| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP CLO & General Counsel | EVP Legal & General Counsel | EVP & General Counsel +3 more
1 company
Patrick R. O'Neil is EVP CLO & General Counsel at IONS. Patrick R. O'Neil's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.4M at current prices.
Historically, Patrick R. O'Neil's trades have earned a middling insider score of 63/100 across 26 rated trades. Over a 12-month horizon, 59.1% of those trades were profitable, with an average 12-month return of -9.2%.
The IONS filings lean toward selling, a net 463,394 shares.
Patrick R. O'Neil has 58 Form 4 filings on record from January 2019 to August 2026, all as EVP CLO & General Counsel at Ionis Pharmaceuticals (IONS), 2019–2026.
The 132 reported transactions were 51 open-market sales, 38 option exercises, 21 option or other derivative awards and 14 other transactions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 31 sales worth about $29.8M.
The largest open-market sale was 89,900 shares of IONS at an average $60.03 on September 3, 2025, about $5.4M. Twelve months later IONS was down 4%.
13 of the 19 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 6 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP CLO & General Counsel | Sell10b5-1 | 3,069 | $80.00 | $245,520.00 | -4.8% | -46.0% | - | |
| Mar 9, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP CLO & General Counsel | Sell10b5-1 | 10,148 | $75.25 | $763,662.37 | -14.0% | -2.4% | - | |
| Jan 30, 2026 | IONS Ionis Pharmaceuticals Inc | EVP CLO & General Counsel | Sell | 6,179 | $83.53 | $516,153.50 | -7.9% | -9.6% | - | |
| Jan 16, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP CLO & General Counsel | Sale+OE | 9,191 | $75.84 | $697,045.44 | -12.2% | -1.4% | - | |
| Oct 6, 2025 | IONS Ionis Pharmaceuticals Inc | EVP CLO & General Counsel | Sale+OE10b5-1 | 13,441 | $69.74 | $937,337.63 | -20.0% | +13.8% | -36.3% | |
| Oct 2, 2025 | IONS Ionis Pharmaceuticals Inc | EVP CLO & General Counsel | Sale+OE10b5-1 | 64,664 | $67.69 | $4,377,054.43 | -53.1% | +15.7% | -36.3% | |
| Sep 30, 2025 | IONS Ionis Pharmaceuticals Inc | EVP CLO & General Counsel | Sale+OE10b5-1 | 25,300 | $64.62 | $1,634,921.48 | -30.7% | +22.3% | -31.7% | |
| Sep 12, 2025 | IONS Ionis Pharmaceuticals Inc | EVP CLO & General Counsel | Sale+OE10b5-1 | 1,700 | $64.58 | $109,787.19 | -2.9% | +25.3% | -14.2% | |
| Sep 9, 2025 | IONS Ionis Pharmaceuticals Inc | EVP CLO & General Counsel | Sale+OE10b5-1 | 21,000 | $64.56 | $1,355,661.30 | -26.9% | +26.6% | -13.0% | |
| Sep 3, 2025 | IONS Ionis Pharmaceuticals Inc | EVP CLO & General Counsel | Sale+OE10b5-1 | 89,900 | $60.03 | $5,396,843.39 | -92.5% | +34.4% | -3.9% |